Abstract YO26
Case summary
As the survival of patients with brain metastases is being prolonged, due to improved systemic therapy, opportunities to use immune checkpoint inhibitor (ICI)s after SRT (stereotactic radiotherapy) or IMRT (Intensity Modulated Radiation Therapy) in patient with brain metastases are increasing. Radiation necrosis is known as a late toxicity of SRT and IMRT. However, few studies have examined the association between ICIs and radiation necrosis. Here we report two cases in which radiation necrosis was exacerbated after ICIs.
Case1: A 30-year-old female diagnosed with nasopharyngeal carcinoma who had direct invasion to the skull base and metastases to the vertebrae. After the concurrent chemoradiation, she had a locoregional recurrence. MRI showed the ring-enhancing lesion around the IMRT-pretreated site of the right temporal lobe, which was considered to be radiation necrosis. One week after the initiation of nivolumab, the patient developed disorientation and a headache. Brain CT showed the exacerbation of radiation necrosis. Corticosteroid administration improved the symptoms. Nivolumab was not reinitiated.
Case2: A 60-year-old male diagnosed with non-small cell lung cancer with brain metastases. He underwent IMRT for the right temporal lobe after undergoing bilateral craniotomy for multiple brain metastases. Because the paralysis progressed, he was performed resection of the brain enhancing lesion. The histopathological examination of the resected brain lesion revealed the presence of diffuse necrosis and gliosis with absence of viable tumor, which was compatible with radiation necrosis. One week after the initiation of atezolizumab, the patient developed hemiparesis. Brain CT showed the exacerbation of radiation necrosis. The patient then started treatment with corticosteroid, and hemiparesis was partly improved. The administration of atezolizumab was discontinued.
Conclusion: We experienced two cases of exacerbation of radiation necrosis following the initiation of the ICIs. Further investigation for the safety of using ICIs in patients with radiation necrosis is warranted.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
134P - Identification, development and validation of a circulating miRNA-based diagnostic signature for early detection of gastric cancer
Presenter: Daisuke Izumi
Session: Poster display session
Resources:
Abstract
135P - The promising key genes associated with tumour microenvironment and prognosis of hepatocellular carcinoma
Presenter: Jing Fang
Session: Poster display session
Resources:
Abstract
136P - Helicobacter pylori-positive gastric diffuse large B-cell lymphoma: A subset with distinct prognostic features
Presenter: Yuan Cheng
Session: Poster display session
Resources:
Abstract
137P - Significant benefit of pyrotinib combined with SHR6390 in patients with multiline-resistant HER2-positive advanced gastric cancer
Presenter: Zuhua Chen
Session: Poster display session
Resources:
Abstract
138P - Incidence of supracarinal lymph node positivity in operated cases of total esophagectomy: Short term results from a tertiary cancer centre
Presenter: Akhil Palod
Session: Poster display session
Resources:
Abstract
139P - Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy
Presenter: Ayberk Besen
Session: Poster display session
Resources:
Abstract
140P - Pancreaticoduodenectomy versus combined neoadjuvant chemotherapy and pancreaticoduodenectomy: Survival patterns among patients with stage II & III periampullary carcinoma
Presenter: Mai Abdelkader
Session: Poster display session
Resources:
Abstract
141P - A 13-gene signature of DNA repair predicts prognosis in gastric cancer patients
Presenter: Jinjia Chang
Session: Poster display session
Resources:
Abstract
142P - Relation between Interleukin -4 (590C/T) gene polymorphism and hepatocellular carcinoma risk in HBV and HCV patients
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract